Insmed Inc (INSM)vsMAIA Biotechnology Inc. (MAIA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MAIA
MAIA Biotechnology Inc.
$1.44
-3.36%
HEALTHCARE · Cap: $87.40M
Smart Verdict
WallStSmart Research — data-driven comparison
MAIA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MAIA
Avoid16
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MAIA
MAIA has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MAIA
The primary concerns for MAIA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while MAIA is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
INSM generates stronger free cash flow (-294M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
MAIA Biotechnology Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing advanced cancer therapies aimed at improving patient outcomes across a variety of cancer types. Utilizing its proprietary technology platforms, MAIA is committed to creating novel drug candidates that harness the immune system to target tumors, addressing significant unmet needs in oncology. With a strong pipeline and a strategic approach to therapeutic development, the company aims to play a crucial role in the biopharmaceutical sector, capitalizing on growth opportunities within the expanding healthcare market.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?